Wealthspire Advisors LLC Has $1.11 Million Position in Novo Nordisk A/S (NYSE:NVO)

Wealthspire Advisors LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 19.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,875 shares of the company’s stock after selling 3,013 shares during the quarter. Wealthspire Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,107,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NVO. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Bristlecone Advisors LLC raised its holdings in Novo Nordisk A/S by 7.9% during the third quarter. Bristlecone Advisors LLC now owns 9,898 shares of the company’s stock valued at $1,179,000 after buying an additional 725 shares in the last quarter. Clear Harbor Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 5.0% in the third quarter. Clear Harbor Asset Management LLC now owns 3,628 shares of the company’s stock worth $432,000 after buying an additional 172 shares during the last quarter. Riggs Asset Managment Co. Inc. boosted its stake in shares of Novo Nordisk A/S by 0.9% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 44,342 shares of the company’s stock worth $5,280,000 after acquiring an additional 390 shares in the last quarter. Finally, Cavalier Investments LLC increased its holdings in shares of Novo Nordisk A/S by 6.5% during the 3rd quarter. Cavalier Investments LLC now owns 22,469 shares of the company’s stock valued at $2,675,000 after acquiring an additional 1,380 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 2.8 %

Shares of NVO opened at $90.58 on Tuesday. The business’s 50 day simple moving average is $85.66 and its 200-day simple moving average is $107.72. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company has a market capitalization of $406.48 billion, a P/E ratio of 27.53, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.